Evaluation of 29 indicators for the prognosis of advanced non‑small cell lung cancer with cytokine‑induced killer cell therapy combined with chemotherapy

Jia,Hejin; Tian,Yaping; Jiang,Chao Guang; Han,Weidong

doi:10.3892/etm.2016.3102

Evaluation of 29 indicators for the prognosis of advanced non‑small cell lung cancer with cytokine‑induced killer cell therapy combined with chemotherapy

Authors:
- Hejin Jia
- Yaping Tian
- Chao Guang Jiang
- Weidong Han
View Affiliations

Affiliations: Biotherapeutic Department, Chinese PLA General Hospital, Beijing 100853, P.R. China, Department of Clinical Biochemistry, State Key Laboratory of Kidney Disease, Chinese PLA General Hospital, Beijing 100853, P.R. China, The Medical Department of Educational Administration, Chinese PLA General Hospital, Beijing 100853, P.R. China
Published online on: February 22, 2016 https://doi.org/10.3892/etm.2016.3102
Pages: 1601-1610
Copyright: © Jia et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to evaluate 29 whole blood or serum indicators to identify factors able to predict clinical outcome following cytokine‑induced killer (CIK) cell therapy combined with chemotherapy in patients with advanced non‑small cell lung cancer (NSCLC), and to evaluate the 5‑year prognosis of the patients. From March 2008 to October 2013, 42 patients with advanced NSCLC (stages III and IV) were enrolled in the study. These patients were from a single hospital, and had been treated with CIK therapy combined with chemotherapy. Evaluation of the correlation between prognosis and age, gender, tumor stage, surgery resection status, number of CIK therapy cycles, tumor subtype, and the differential whole blood or serum indicators were analyzed by Kaplan‑Meier methods and the log‑rank test. The prognostic factors were analyzed by Cox proportional models. The median progression‑free survival (mPFS) time of patients with high expression levels of albumin [20.0 months; 95% confidence interval (CI): 17.4‑22.6 months] was significantly longer than the mPFS for patients with low expression levels of albumin (36.0 months; 95% CI: 24.7‑47.3 months) (P=0.034). Other factors demonstrated no significant difference. Following analysis using the Cox proportional hazards regression model, the number of CIK therapy cycles (P=0.041) and the expression level of albumin (P=0.038) were revealed to be independent prognostic factors following the use of CIK cell therapy combined with chemotherapy for patients with advanced NSCLC. The risk of adverse outcomes in patients receiving ≥4 CIK therapy cycles and in patients with increased expression levels of albumin were 0.38 (95% CI: 0.14‑1.13) and 0.32 (95% CI: 0.10‑1.24)‑fold those of patients receiving <4 CIK therapy cycles and with decreased expression levels of albumin, respectively. The serum albumin concentration may therefore be a predictor of the 5‑year survival rate of patients with advanced NSCLC treated with CIK cell therapy combined with chemotherapy; patients with high expression levels of albumin may have a better prognosis in comparison with patients with low expression levels of albumin.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
2	She J, Yang P, Hong Q and Bai C: Lung cancer in China: Challenges and interventions. Chest. 143:1117–1126. 2013. View Article : Google Scholar : PubMed/NCBI
3	Molina JR, Yang P, Cassivi SD, Schild SE and Adjei AA: Non-small cell lung cancer: Epidemiology, risk factors, treatment and survivorship. Mayo Clin Proc. 83:584–594. 2008. View Article : Google Scholar : PubMed/NCBI
4	Spiro SG, Tanner NT, Silvestri GA, Janes SM, Lim E, Vansteenkiste JF and Pirker R: Lung cancer: Progress in diagnosis, staging and therapy. Respirology. 15:44–50. 2010. View Article : Google Scholar : PubMed/NCBI
5	Pallis AG, Serfass L, Dziadziusko R, van Meerbeeck JP, Fennell D, Lacombe D, Welch J and Gridelli C: Targeted therapies in the treatment of advanced/metastatic NSCLC. Eur J Cancer. 45:2473–2487. 2009. View Article : Google Scholar : PubMed/NCBI
6	Fridman WH, Pagès F, Sautès-Fridman C and Galon J: The immune contexture in human tumours: Impact on clinical outcome. Nat Rev Cancer. 12:298–306. 2012. View Article : Google Scholar : PubMed/NCBI
7	Fischbach MA, Bluestone JA and Lim WA: Cell-based therapeutics: The next pillar of medicine. Sci Transl Med. 5:179ps72013. View Article : Google Scholar : PubMed/NCBI
8	Sangiolo D: Cytokine induced killer cells as promising immunotherapy for solid tumors. J Cancer. 2:363–368. 2011. View Article : Google Scholar : PubMed/NCBI
9	Lu PH and Negrin RS: A novel population of expanded human CD3⁺CD56⁺ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol. 153:1687–1696. 1994.PubMed/NCBI
10	Jiang J, Wu C and Lu B: Cytokine-induced killer cells promote antitumor immunity. J Transl Med. 11:832013. View Article : Google Scholar : PubMed/NCBI
11	Wang FS, Liu MX, Zhang B, Shi M, Lei ZY, Sun WB, Du QY and Chen JM: Antitumor activities of human autologous cytokine-induced killer (CIK) cells against hepatocellular carcinoma cells in vitro and in vivo. World J Gastroenterol. 8:464–468. 2002. View Article : Google Scholar : PubMed/NCBI
12	Yang L, Ren B, Li H, Yu J, Cao S, Hao X and Ren X: Enhanced antitumor effects of DC-activated CIKs to chemotherapy treatment in a single cohort of advanced non-small-cell lung cancer patients. Cancer Immunol Immunother. 62:65–73. 2013. View Article : Google Scholar : PubMed/NCBI
13	Gammaitoni L, Giraudo L, Leuci V, Todorovic M, Mesiano G, Picciotto F, Pisacane A, Zaccagna A, Volpe MG, Gallo S, et al: Effective activity of cytokine-induced killer cells against autologous metastatic melanoma including cells with stemness features. Clin Cancer Res. 19:4347–4358. 2013. View Article : Google Scholar : PubMed/NCBI
14	Jakel CE, Vogt A, Gonzalez-Carmona MA and Schmidt-Wolf IG: Clinical studies applying cytokine-induced killer cells for the treatment of gastrointestinal tumors. J Immunol Res. 2014:8972142014. View Article : Google Scholar : PubMed/NCBI
15	Zhang Y, Wang J, Wang Y, Lu XC, Fan H, Liu Y, Zhang Y, Feng KC, Zhang WY, Chen MX, et al: Autologous CIK cell immunotherapy in patients with renal cell carcinoma after radical nephrectomy. Clin Dev Immunol. 2013:1956912013. View Article : Google Scholar : PubMed/NCBI
16	Kim JS, Chung IS, Lim SH, Park Y, Park MJ, Kim JY, Kim YG, Hong JT, Kim Y and Han SB: Preclinical and clinical studies on cytokine-induced killer cells for the treatment of renal cell carcinoma. Arch Pharm Res. 37:559–566. 2014. View Article : Google Scholar : PubMed/NCBI
17	Wu C, Jiang J, Shi L and Xu N: Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small cell lung cancer. Anticancer Res. 28:3997–4002. 2008.PubMed/NCBI
18	Shi SB, Ma TH, Li CH and Tang XY: Effect of maintenance therapy with dendritic cells: Cytokine-induced killer cells in patients with advanced non-small cell lung cancer. Tumori. 98:314–319. 2012.PubMed/NCBI
19	Han RX, Liu X, Pan P, Jia YJ and Yu JC: Effectiveness and safety of chemotherapy combined with dendritic cells co-cultured with cytokine-induced killer cells in the treatment of advanced non-small-cell lung cancer: A systematic review and meta-analysis. PLoS One. 9:e1089582014. View Article : Google Scholar : PubMed/NCBI
20	Chen Y, Lin G, Guo ZQ, Zhou ZF, He ZY and Ye YB: Effects of MICA expression on the prognosis of advanced non-small cell lung cancer and the efficacy of CIK therapy. PloS One. 8:e690442013. View Article : Google Scholar : PubMed/NCBI
21	Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, et al: Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 515:563–567. 2014. View Article : Google Scholar : PubMed/NCBI
22	González-Cao M: Immunotherapy for lung cancer. Transl Lung Cancer Res. 4:675–677. 2015.PubMed/NCBI
23	Mahoney KM and Atkins MB: Prognostic and predictive markers for the new immunotherapies. Oncology 28 Suppl. 3:39–48. 2014.
24	Wang Y, Dai H, Li H, Lv H, Wang T, Fu X and Han W: Growth of human colorectal cancer SW1116 cells is inhibited by cytokine-induced killer cells. Clin Dev Immunol. 2011:6214142011. View Article : Google Scholar : PubMed/NCBI
25	Gehrmann U, Hiltbrunner S, Georgoudaki AM, Karlsson MC, Näslund TI and Gabrielsson S: Synergistic induction of adaptive antitumor immunity by codelivery of antigen with α-galactosylceramide on exosomes. Cancer Res. 73:3865–3876. 2013. View Article : Google Scholar : PubMed/NCBI
26	Belardelli F and Ferrantini M: Cytokines as a link between innate and adaptive antitumor immunity. Trends Immunol. 23:201–208. 2002. View Article : Google Scholar : PubMed/NCBI
27	Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, Yokoyama WM and Ugolini S: Innate or adaptive immunity? The example of natural killer cells. Science. 331:44–49. 2011. View Article : Google Scholar : PubMed/NCBI
28	Wu F, Wang ZB, Lu P, Xu ZL, Chen WZ, Zhu H and Jin CB: Activated anti-tumor immunity in cancer patients after high intensity focused ultrasound ablation. Ultrasound Med Biol. 30:1217–1222. 2004. View Article : Google Scholar : PubMed/NCBI
29	Ciernik IF, Berzofsky JA and Carbone DP: Induction of cytotoxic T lymphocytes and antitumor immunity with DNA vaccines expressing single T cell epitopes. J Immunol. 156:2369–2375. 1996.PubMed/NCBI
30	Kirkwood JM, Butterfield LH, Tarhini AA, Zarour H, Kalinski P and Ferrone S: Immunotherapy of cancer in 2012. CA Cancer J Clin. 62:309–335. 2012. View Article : Google Scholar : PubMed/NCBI
31	Li R, Wang C, Liu L, Du C, Cao S, Yu J, Wang SE, Hao X, Ren X and Li H: Autologous cytokine-induced killer cell immunotherapy in lung cancer: A phase II clinical study. Cancer Immunol Immunother. 61:2125–2133. 2012. View Article : Google Scholar : PubMed/NCBI
32	Li DP, Li W, Feng J, Chen K and Tao M: Adjuvant chemotherapy with sequential cytokine-induced killer (CIK) cells in stage IB non-small cell lung cancer. Oncol Res. 22:67–74. 2015. View Article : Google Scholar : PubMed/NCBI
33	Zhong R, Han B and Zhong H: A prospective study of the efficacy of a combination of autologous dendritic cells, cytokine-induced killer cells, and chemotherapy in advanced non-small cell lung cancer patients. Tumour Biol. 35:987–994. 2014. View Article : Google Scholar : PubMed/NCBI
34	Zhong R, Teng J, Han B and Zhong H: Dendritic cells combining with cytokine-induced killer cells synergize chemotherapy in patients with late-stage non-small cell lung cancer. Cancer Immunol Immunother. 60:1497–1502. 2011. View Article : Google Scholar : PubMed/NCBI
35	Li Y, Huang SL, Wu YF, Wei J, Bao R and Zhou DH: Expansion of CIK/NK cells from cord blood by using different combinations of stem cell factor, FLT3 ligand and interleukin 2, 7, 15 in vitro. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 12:350–354. 2004.(In Chinese). PubMed/NCBI
36	Li Y, Schmidt-Wolf IG, Wu YF, Huang SL, Wei J, Fang J, Huang K and Zhou DH: Optimized protocols for generation of cord blood-derived cytokine-induced killer/natural killer cells. Anticancer Res. 30:3493–3499. 2010.PubMed/NCBI
37	Ritchie RF, Palomaki GE, Neveux LM, Navolotskaia O, Ledue TB and Craig WY: Reference distributions for the negative acute-phase serum protein–s, albumin, transferrin and transthyretin: A practical, simple and clinically relevant approach in a large cohort. J Clin Lab Anal. 13:273–279. 1999. View Article : Google Scholar : PubMed/NCBI
38	Don BR and Kaysen G: Serum albumin: Relationship to inflammation and nutrition. Semin Dial. 17:432–437. 2004. View Article : Google Scholar : PubMed/NCBI
39	von Meyenfeldt M: Cancer-associated malnutrition: An introduction. Eur J Oncol Nurs. 9(Suppl 2): S35–S38. 2005. View Article : Google Scholar : PubMed/NCBI
40	Gupta D and Lis CG: Pretreatment serum albumin as a predictor of cancer survival: A systematic review of the epidemiological literature. Nutr J. 9:692010. View Article : Google Scholar : PubMed/NCBI
41	Yeun JY and Kaysen GA: Factors influencing serum albumin in dialysis patients. Am J Kidney Dis. 32(Suppl 4): S118–S125. 1998. View Article : Google Scholar : PubMed/NCBI
42	Siddiqui A, Heinzerling J, Livingston EH and Huerta S: Predictors of early mortality in veteran patients with pancreatic cancer. Am J Surg. 194:362–366. 2007. View Article : Google Scholar : PubMed/NCBI
43	Onate-Ocana LF, Aiello-Crocifoglio V, Gallardo-Rincón D, Herrera-Goepfert R, Brom-Valladares R, Carrillo JF, Cervera E and Mohar-Betancourt A: Serum albumin as a significant prognostic factor for patients with gastric carcinoma. Ann Surg Oncol. 14:381–389. 2007. View Article : Google Scholar : PubMed/NCBI
44	Lis CG, Grutsch JF, Vashi PG and Lammersfeld CA: Is serum albumin an independent predictor of survival in patients with breast cancer? JPEN J Parenter Enteral Nutr. 27:10–15. 2003. View Article : Google Scholar : PubMed/NCBI
45	Seve P, Ray-Coquard I, Trillet-Lenoir V, Sawyer M, Hanson J, Broussolle C, Negrier S, Dumontet C and Mackey JR: Low serum albumin levels and liver metastasis are powerful prognostic markers for survival in patients with carcinomas of unknown primary site. Cancer. 107:2698–2705. 2006. View Article : Google Scholar : PubMed/NCBI
46	Burkholder B, Huang RY, Burgess R, Luo S, Jones VS, Zhang W, Lv ZQ, Gao CY, Wang BL, Zhang YM and Huang RP: Tumor-induced perturbations of cytokines and immune cell networks. Biochim Biophys Acta. 1845:182–201. 2014.PubMed/NCBI
47	Souza SL, Da Montalli Assumpção LV and Ward LS: Impact of previous thyroid autoimmune diseases on prognosis of patients with well-differentiated thyroid cancer. Thyroid. 13:491–495. 2003. View Article : Google Scholar : PubMed/NCBI
48	Krauze MT, Tarhini A, Gogas H and Kirkwood JM: Prognostic significance of autoimmunity during treatment of melanoma with interferon. Semin Immunopathol. 33:385–391. 2011. View Article : Google Scholar : PubMed/NCBI
49	Weber J: Ipilimumab: Controversies in its development, utility and autoimmune adverse events. Cancer Immunol Immunother. 58:823–830. 2009. View Article : Google Scholar : PubMed/NCBI
50	Braumuller H, Wieder T, Brenner E, Aßmann S, Hahn M, Alkhaled M, Schilbach K, Essmann F, Kneilling M, Griessinger C, et al: T-helper-1-cell cytokines drive cancer into senescence. Nature. 494:361–365. 2013. View Article : Google Scholar : PubMed/NCBI
51	Salih HR, Rammensee HG and Steinle A: Cutting edge: Down-regulation of MICA on human tumors by proteolytic shedding. J Immunol. 169:4098–4102. 2002. View Article : Google Scholar : PubMed/NCBI
52	Ascierto PA, Capone M, Urba WJ, Bifulco CB, Botti G, Lugli A, Marincola FM, Ciliberto G, Galon J and Fox BA: The additional facet of immunoscore: Immunoprofiling as a possible predictive tool for cancer treatment. J Transl Med. 11:542013. View Article : Google Scholar : PubMed/NCBI